The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents

Blood Cancer J. 2017 Dec 15;7(12):649. doi: 10.1038/s41408-017-0019-6.

Authors

Affiliations

¹ Department of Biomedicine and Molecular Medicine, University of Catania, Catania, Italy. sandrina.romano@gmail.com.
² Division of Hematology, Azienda Policlinico-Vittorio Emanuele-Catania, Catania, Italy.
³ Hematology, Department of Clinical Medicine, University Federico II, Napoli, Italy.
⁴ Department of Biomedicine and Molecular Medicine, University of Catania, Catania, Italy.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Disease-Free Survival
Female
Humans
Leukocyte Count / methods*
Lymphocyte Count
Male
Middle Aged
Monocytes
Multiple Myeloma / blood*
Multiple Myeloma / drug therapy*
Multiple Myeloma / mortality*
Neutrophils
Prognosis